These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9358333)

  • 1. Adaptive survival trials.
    Rosenberger WF; Seshaiyer P
    J Biopharm Stat; 1997 Nov; 7(4):617-24. PubMed ID: 9358333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive biased-coin designs for skewing the allocation proportion in clinical trials with normal responses.
    Atkinson AC; Biswas A
    Stat Med; 2005 Aug; 24(16):2477-92. PubMed ID: 16007571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials.
    Biswas A; Bhattacharya R
    J Biopharm Stat; 2018; 28(5):809-823. PubMed ID: 29913107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing competing demands in the implementation of response-adaptive randomization in a large multicenter phase III acute stroke trial.
    Zhao W; Durkalski V
    Stat Med; 2014 Oct; 33(23):4043-52. PubMed ID: 24849843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preserving the allocation ratio at every allocation with biased coin randomization and minimization in studies with unequal allocation.
    Kuznetsova OM; Tymofyeyev Y
    Stat Med; 2012 Apr; 31(8):701-23. PubMed ID: 22161821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exact group-sequential designs for clinical trials with randomized play-the-winner allocation.
    Stallard N; Rosenberger WF
    Stat Med; 2002 Feb; 21(4):467-80. PubMed ID: 11836730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-randomization tests in clinical trials.
    Proschan MA; Dodd LE
    Stat Med; 2019 May; 38(12):2292-2302. PubMed ID: 30672002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small n sequential multiple assignment randomized trial design for use in rare disease research.
    Tamura RN; Krischer JP; Pagnoux C; Micheletti R; Grayson PC; Chen YF; Merkel PA
    Contemp Clin Trials; 2016 Jan; 46():48-51. PubMed ID: 26586608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weighted re-randomization tests for minimization with unbalanced allocation.
    Han B; Yu M; McEntegart D
    Pharm Stat; 2013; 12(4):243-53. PubMed ID: 23760923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.
    Thall P; Fox P; Wathen J
    Ann Oncol; 2015 Aug; 26(8):1621-8. PubMed ID: 25979922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of simulation to compare the performance of minimization with stratified blocked randomization.
    Toorawa R; Adena M; Donovan M; Jones S; Conlon J
    Pharm Stat; 2009; 8(4):264-78. PubMed ID: 18756580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
    Potthoff RF; Halabi S
    Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covariate-adjusted response-adaptive designs for binary response.
    Rosenberger WF; Vidyashankar AN; Agarwal DK
    J Biopharm Stat; 2001 Nov; 11(4):227-36. PubMed ID: 12018777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical methodology of phase III cancer clinical trials: advances and future perspectives.
    Sylvester R; Van Glabbeke M; Collette L; Suciu S; Baron B; Legrand C; Gorlia T; Collins G; Coens C; Declerck L; Therasse P
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S162-8. PubMed ID: 11858987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response-adaptive randomization for clinical trials with adjustment for covariate imbalance.
    Ning J; Huang X
    Stat Med; 2010 Jul; 29(17):1761-8. PubMed ID: 20658546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
    Atkinson AC; Biswas A
    Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials.
    Nomura S; Shinozaki T; Hamada C
    J Biopharm Stat; 2020 Mar; 30(2):377-401. PubMed ID: 31820674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.